Welcome. Prostate diseases are a major health burden for American men. Prostate cancer is still #1 in incidence, and benign prostate enlargement will affect the majority of men, to varying degrees, as they age beyond 50. In many men, these two problems co-exist. While in years past, the PSA test and a digital exam were the only thing we could do to assess the prostate, we now have a new arsenal of genomic and biomarker tests that can help us in decision making. These new tests, in particular, have the potential to solve some of the issues with prostate cancer screening when PSA alone is used.
Satyan K. Shah, M.D.
Director of Robotic Surgery
Director of Minimally Invasive Urologic Surgery
University of New Mexico Cancer Center